| Literature DB >> 27377429 |
Fiona Yan-Yee Ho1, Wing-Fai Yeung2, Tommy Ho-Yee Ng3, Christian S Chan1.
Abstract
Stepped care is an increasingly popular treatment model for common mental health disorders, given the large discrepancy between the demand and supply of healthcare service available. In this review, we aim to compare the efficacy and cost-effectiveness of stepped care prevention and treatment with care-as-usual (CAU) or waiting-list control for depressive and/or anxiety disorders. 5 databases were utilized from its earliest available records up until April 2015. 10 randomized controlled trials were included in this review, of which 6 examined stepped care prevention and 4 examined stepped care treatment, specifically including ones regarding depressive and/or anxiety disorders. Only trials with self-help as a treatment component were included. Results showed stepped care treatment revealed a significantly better performance than CAU in reducing anxiety symptoms, and the treatment response rate of anxiety disorders was significantly higher in stepped care treatment than in CAU. No significant difference was found between stepped care prevention/treatment and CAU in preventing anxiety and/or depressive disorders and improving depressive symptoms. In conclusion, stepped care model appeared to be better than CAU in treating anxiety disorders. The model has the potential to reduce the burden on existing resources in mental health and increase the reach and availability of service.Entities:
Mesh:
Year: 2016 PMID: 27377429 PMCID: PMC4932532 DOI: 10.1038/srep29281
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Selection Flow of Trials for Inclusion in the Review.
Characteristics of Randomized Controlled Trials of Stepped Care Treatment and Prevention for Depressive and/or Anxiety Disorders.
| No. | Study authors (year) | Country/type of participants | Mean age ( | Diagnostic criteria | Design | Collaboration | Sample size (subgroup) | Assess-ments | Stepped care intervention | Control intervention | Outcome measure | Major results reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Apil | Netherlands | 65.8 (8.4) | Had received treatment for depression | 2-parallel arms (SC, CAU) | Nurses | 136 (74/62) | 6, 12, 24 mo | 1) Watchful waiting; 2) SH CBT; 3) FTF CBT; 4) referral to physicians or psychotherapists | CAU (unrestricted access to any form of health care) | CES-D, GGZ, Tic-P | No significant difference between SC and CAU in incidence of depression at 12-mo. SC required new treatment significantly>CAU. |
| 2 | Dozeman | Netherlands | 84.4 (6.6) | CES-D ≥8, MINI for depressive or anxiety disorders | 2-parallel arms (SC, CAU) | General practitioners, mental health specialists, nurses | 185 (93/92) | 1, 4, 7, 10 mo | 1) Watchful waiting; 2) SH activity-scheduling; 3) FTF life review; 4) referral to general practitioners or mental health specialists | CAU (unrestricted access to any form of health care) | MINI, CES-D, HADS-A, loneliness scale, Tic-P, ADL, GARS | SC significantly reduced the risk of MDD incidence in comparison with CAU. |
| 3 | van’t Veer-Tazelaar | Netherlands | 81.4 (3.7) | CES-D ≥16, MINI for depressive or anxiety disorders | 2-parallel arms (SC, CAU) | Nurses, primary care physicians | 170 (86/84) | 6, 12, 18, 24 mo | 1) Watchful waiting; 2) SH CBT; 3) FTF PST; 4) referral to primary care physicians | CAU (unrestricted access to any form of health care) | CES-D, MINI | SC significantly halved the cumulative incidence rate of DSM-IV depression or anxiety at 12 and 24-mo FU. |
| 4 | Zhang | Hong Kong | NA (NA) | CES-D ≥16 or HADS-A ≥6 | 2-parallel arms (SC, CAU) | Social workers, family medicine doctors | 240 (121/119) | 3, 6, 9, 12, 15 mo | 1) Watchful waiting; 2) guided SH; 3) problem solving treatment; 4) family doctor treatment | CAU (unrestricted access to any form of health care) | CES-D, HADS-A | No significant difference between SC and CAU in of SCP in preventing the onset of MDD and GAD. |
| 5 | Muntingh | Netherlands | 46.5 (15.5) | DSM-IV for PD and GAD | 2-parallel arms (SC, CAU) | Care managers, general practitioners, psychiatrists | 180 (114/66) | 3, 6, 9, 12 mo | 1) Guided SH CBT; 2) FTF CBT; 3) pharmacotherapy | CAU (unrestricted access to any form of health care) | BAI, PHQ, SF-36, EQ-5D | SC significantly gained more in BAI score than CAU. |
| 6 | Oosterbaan | Netherlands | 38.0 (12.0) | MINI for depressive, anxiety and stress-related disorders | 2-parallel arms (SC, CAU) | General practitioners, psychologists, nurses | 158 (94/64) | 4, 8, 12 mo | 1) Guided SH CBT in primary care; 2) FTF CBT in mental healthcare; 3) intensive psychiatric treatment in day care clinic | CAU (unrestricted access to any form of health care) | CGI-I, CGI-S, HRSA, CES-D, FQ, SCL-90-R, SF-36 | SC significantly superior to CAU responders at 4-mo mid-test. No significant difference between SC and CAU at 8 and 12-mo FU. |
| 7 | Seekles | Netherlands | 50.2 (11.2) | DSM-IV for depressive and/or anxiety disorders | 2-parallel arms (SC, CAU) | General practitioners, psycholo-gists, psychiatric nurses | 120 (60/60) | 8, 16, 24 wk | 1) Watchful waiting; 2) guided SH CBT; 3) FTF PST; 4) referral | CAU (unrestricted access to any form of health care) | IDS, HADS, WSAS, CIDI | Both groups significantly decreased in depression and anxiety over time. No significant difference between SC and CAU in depression and anxiety. |
| 8 | Tolin | NR | 33.9 (13.3) | DSM-IV for OCD ≥1 year, Y-BOCS ≥16 and CGI ≥4 | 2-parallel arms (SC, CAU) | Therapists | 30 (18/12) | 1, 3 mo | 1) Guided SH ERP; 2) FTF ERP | Standard ERP | Y-BOCS, CGI-S and CGI-I | No significant difference between SC and CAU in Y-BOCS and treatment satisfaction. |
ADL, activity of daily living; BAI, Beck Anxiety Inventory; CAU, care-as-usual; CBT, cognitive-behavioral therapy; CES-D, Centre of Epidemiological Studies–Depression scale; CGI-I, Clinical Global Impression–Improvement Scale; CGI-S, Clinical Global Impression–Severity Scale; CIDI, Composite International Diagnostic Interview; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; ERP, exposure and response prevention; EQ-5D, EuroQol-5D; FQ, Fear Questionnaire; FTF, face-to-face; FU, follow-up; GAD, generalized anxiety disorder; GARS, Groningen Activity Restriction Scale; GGZ, GGZ thermometer; HADS-A, Hospital Anxiety and Depression Scale–Anxiety; HRSA, Hamilton Rating Scale for Anxiety; IDS, Inventory of Depressive Symptomatology; MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; NR, not reported; OCD, obsessive-compulsive disorder; PD, panic disorder; PHQ, Patient Health Questionnaire; PST, problem-solving treatment; SC, stepped care; SCL-90-R, Symptom Checklist–90–Revised; SF-36, Short-Form Health Survey–36 items; SH, self-help; Tic-P, Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness; WSAS, Work and Social Adjustment Scale; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
Source of Treatment Content, Treatment Type, Recruitment Method, Attrition Rate, Reasons for Attrition, and Stepping Up Criteria.
| No. | Study authors (year) | Treatment content | Recruitment | Cumulative attrition rate (step no./assessment) | Stepping up criteria (direct to the last step) |
|---|---|---|---|---|---|
| 1 | Apil | Step 2–SH CBT:Based on | Psychiatric center | SC: 16.9% (PT) | CES-D >15 (diagnosis of depression by MINI) |
| 2 | Dozeman | Step 2–SH activity-scheduling:Based on | Residential homes | SC: 18.9% (PT)CAU: 10.8% (PT) | CES-D <5 improvement (DSM-IV diagnosis of depressive or anxiety disorder) |
| 3 | van’t Veer-Tazelaar | Step 2–SH CBT:Based on | Primary care | SC: 11.8% (6 mo-PT), 14.7% (12 mo-FU), 15.3% (18 mo-FU), 15.9% (24 mo-FU)CAU: 4.1% (6 mo-PT), 4.7% (12 mo-FU), 5.9% (18 mo-FU), 8.2% (24 mo-FU) | CES-D ≥16 (diagnosis of depressive or anxiety disorders by MINI) |
| 4 | Zhang | Step 2–Guided SH instruction through telephone:Based on | Primary clinics | SC: 6.6% (3 mo), 10.7% (6 mo), 10.7% (9 mo), 12.4% (12 mo-PT), 14.0% (15 mo-FU)CAU: 6.7% (3 mo), 8.4% (6 mo), 10.9% (9 mo), 11.8% (12 mo-PT), 15.1% (15 mo-FU) | CES-D ≥16 or HADS-A ≥6, without the SCID diagnosed MDD or GAD (NR) |
| 5 | Muntingh | Step 1–Guided SH CBT:Provided with psychoeducation, cognitive behavioural exercises and a guided relaxation CD (book) +consultationStep 2–FTF CBT:Cognitive therapy and exposure+workbook | Primary care | NR | BAI >11 or BAI <50% score reduction (NR) |
| 6 | Oosterbaan | Step 1–Guided SH CBT:Depression: Based on | Mental health care center | SC: 8.9% (PT), 16.5% (FU)CAU: 3.2% (PT), 7.6% (FU) | CGI-S ≥3 (depression with psychotic features, actively suicidal or family of the patient was overly strained due to psychiatric disorder) |
| 7 | Seekles | Step 2–Guided SH CBT:PST (book/Internet)/Exposure therapy for phobia (book) +feedbackStep 3–FTF PST:Based on Problem Solving Treatment for Anxiety and Depression: A Practical Guide | Mental health centers | SC: 29.2% (PT)CAU: NR | IDS ≥14, HADS ≥8 and WSAS ≥6 (WSAS ≥8 on 3 of the 4 daily functioning domains) |
| 8 | Tolin | Step 1–Guided SH ERP:Based on | NR | SC: 20.0% (PT)CAU: 6.7% (PT) | Y-BOCS >13 (Y-BOCS >13) |
BAI, Beck Anxiety Inventory; CAU, care-as-usual; CBT, cognitive-behavioral therapy; CES-D, Centre of Epidemiological Studies–Depression scale; CGI-S, Clinical Global Impression–Severity Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; FTF, face-to-face; FU, follow-up; GAD, generalized anxiety disorder; HADS, Hospital Anxiety and Depression Scale; IDS, Inventory of Depressive Symptomatology; MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; NR, not reported; PST, problem-solving treatment; PT, posttreatment; SC, stepped care; SCID, Structured Clinical Interview for DSM-IV; SH, self-help; WSAS, Work and Social Adjustment Scale; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
Figure 2Stepped Care Treatment vs. CAU control on the Incidence of Anxiety and/or Depressive Disorders at Immediate Posttreatment.
Figure 3Stepped Care Treatment vs. CAU control on Anxiety Symptoms at Immediate Posttreatment.